{"id":45981,"date":"2025-11-06T11:32:37","date_gmt":"2025-11-06T03:32:37","guid":{"rendered":"https:\/\/flcube.com\/?p=45981"},"modified":"2025-11-06T14:13:26","modified_gmt":"2025-11-06T06:13:26","slug":"hbms-subsidiary-nona-biosciences-teams-up-with-umoja-biopharma-to-co%e2%80%91develop-in%e2%80%91vivo-car%e2%80%91t-platforms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45981","title":{"rendered":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>HBM Holdings Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>)<\/strong> announced that its wholly\u2011owned subsidiary <strong>Nona Biosciences (Suzhou) Co., Ltd.<\/strong> has signed an <strong>evaluation\u2011and\u2011license agreement<\/strong> with <strong>Umoja Biopharma, Inc.<\/strong>. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of <strong>in\u2011vivo CAR\u2011T cell therapeutics<\/strong> by merging Nona\u2019s <strong>HCAb Harbour\u2011Mice<\/strong> and <strong>NonaCarFx<\/strong> discovery platforms with Umoja\u2019s <strong>VivoVec<\/strong> gene\u2011delivery system.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Role<\/th><th>Financial Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Nona Biosciences<\/strong><\/td><td>Licensor of HCAb Harbour\u2011Mice &amp; NonaCarFx platforms<\/td><td>Up\u2011front cash payment, optional\u2011exercise fees, and milestone payments linked to each discovery &amp; development program<\/td><\/tr><tr><td><strong>Umoja Biopharma<\/strong><\/td><td>Licensee &amp; sole developer\/commercializer<\/td><td>Assumes all downstream R&amp;D, IND filing, clinical trials, and commercialization costs<\/td><\/tr><tr><td><strong>HBM Holdings<\/strong><\/td><td>Indirect benefactor (parent)<\/td><td>Receives Nona\u2019s share of payments; no direct obligations under the agreement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-synergy\">Technology Synergy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HCAb Harbour\u2011Mice<\/strong> \u2013 Engineered mouse strains that produce fully human heavy\u2011chain\u2011only antibodies (HCAbs) with high affinity and developability.<\/li>\n\n\n\n<li><strong>NonaCarFx Platform<\/strong> \u2013 Rapid pipeline for converting HCAbs into CAR constructs tailored for in\u2011vivo expression.<\/li>\n\n\n\n<li><strong>VivoVec (Umoja)<\/strong> \u2013 Non\u2011viral, lipid\u2011nanoparticle\u2011based delivery system that administers CAR\u2011encoding mRNA directly to a patient\u2019s T cells, bypassing ex\u2011vivo cell manufacturing.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Combined, the platforms enable \u201cplug\u2011and\u2011play\u201d generation of CAR\u2011T therapies that can be administered as a single injection, potentially lowering cost and expanding access for both oncology and autoimmune indications.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Accelerated Pipeline<\/strong> \u2013 Leveraging both companies\u2019 pre\u2011clinical assets could shorten the time\u2011to\u2011clinic for new CAR\u2011T candidates.<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong> \u2013 In\u2011vivo CAR\u2011T delivery addresses the scalability and logistical challenges that have limited broader adoption of traditional ex\u2011vivo CAR\u2011T products.<\/li>\n\n\n\n<li><strong>Revenue Upside for HBM<\/strong> \u2013 The upfront and milestone structure provides immediate cash inflow and long\u2011term upside without requiring HBM to fund downstream development.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-amp-next-steps\">Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Discovery Phase<\/strong> \u2013 Both parties will evaluate up to <strong>four initial antigen targets<\/strong> (two oncology, two autoimmune) within the next 12\u202fmonths.<\/li>\n\n\n\n<li><strong>Milestone Timeline<\/strong> \u2013 First IND\u2011enabling studies are slated for <strong>Q2\u202f2026<\/strong>, with potential <strong>US$30\u202fmillion<\/strong> cumulative milestones if two programs advance to clinical trials.<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong> \u2013 Umoja plans to pursue <strong>Fast Track<\/strong> designations in the U.S. and <strong>Priority Review<\/strong> in China for the most promising candidates.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration, development timelines, and regulatory expectations. Actual results may differ due to clinical outcomes, regulatory decisions, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110501913_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025110501913_c.\"><\/object><a id=\"wp-block-file--media-e8562ff1-a545-4d7b-9790-0f038bceb3da\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110501913_c.pdf\">2025110501913_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110501913_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e8562ff1-a545-4d7b-9790-0f038bceb3da\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":45996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[21,129,916,128,1727],"class_list":["post-45981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-car-t","tag-hbm-holdings","tag-hkg-2142","tag-nona-biosciences","tag-umoja-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45981\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms\" \/>\n<meta property=\"og:description\" content=\"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45981\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-06T03:32:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-06T06:13:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms\",\"datePublished\":\"2025-11-06T03:32:37+00:00\",\"dateModified\":\"2025-11-06T06:13:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981\"},\"wordCount\":426,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0603.webp\",\"keywords\":[\"CAR-T\",\"HBM Holdings\",\"HKG: 2142\",\"Nona Biosciences\",\"Umoja Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45981#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45981\",\"name\":\"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0603.webp\",\"datePublished\":\"2025-11-06T03:32:37+00:00\",\"dateModified\":\"2025-11-06T06:13:26+00:00\",\"description\":\"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45981\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Siemens Shanghai Gains NMPA Clearance for Prostate\u2011Cancer AI Detection Software\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45981#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms - Insight, China&#039;s Pharmaceutical Industry","description":"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45981","og_locale":"en_US","og_type":"article","og_title":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms","og_description":"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.","og_url":"https:\/\/flcube.com\/?p=45981","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-06T03:32:37+00:00","article_modified_time":"2025-11-06T06:13:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45981#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45981"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms","datePublished":"2025-11-06T03:32:37+00:00","dateModified":"2025-11-06T06:13:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45981"},"wordCount":426,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45981#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","keywords":["CAR-T","HBM Holdings","HKG: 2142","Nona Biosciences","Umoja Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45981#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45981","url":"https:\/\/flcube.com\/?p=45981","name":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45981#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45981#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","datePublished":"2025-11-06T03:32:37+00:00","dateModified":"2025-11-06T06:13:26+00:00","description":"HBM Holdings Limited (HKG: 2142) announced that its wholly\u2011owned subsidiary Nona Biosciences (Suzhou) Co., Ltd. has signed an evaluation\u2011and\u2011license agreement with Umoja Biopharma, Inc.. The deal expands the strategic partnership first forged in September\u202f2024 and aims to generate a pipeline of in\u2011vivo CAR\u2011T cell therapeutics by merging Nona\u2019s HCAb Harbour\u2011Mice and NonaCarFx discovery platforms with Umoja\u2019s VivoVec gene\u2011delivery system.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45981#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45981"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45981#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","width":1080,"height":608,"caption":"Siemens Shanghai Gains NMPA Clearance for Prostate\u2011Cancer AI Detection Software"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45981#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HBM\u2019s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co\u2011Develop In\u2011Vivo CAR\u2011T Platforms"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45981"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45981\/revisions"}],"predecessor-version":[{"id":45983,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45981\/revisions\/45983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45996"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}